Join the Asthma - Maintenance group to help and get support from people like you.
Asthma - Maintenance News (Page 3)
Related terms: Asthma, Prevention
Tezepelumab Reduces Mucus Plugs in Adults With Uncontrolled Asthma
FRIDAY, Sept. 29, 2023 – Tezepelumab is associated with a reduction in occlusive mucus plugs versus placebo in adults with uncontrolled asthma, according to a study published in the October issue of...
Bacteria at Day Care Might Raise Kids' Odds for Asthma
TUESDAY, Sept. 12, 2023 – Certain combinations of bacteria found in dust in children’s day care settings may have an impact on their young lungs. Researchers are trying to understand whether a...
Healthy, Diverse Infant Microbiome Could Shield Kids From Asthma
MONDAY, Sept. 11, 2023 – Babies who have more mature microbes in their gut are less likely to have allergy-related wheezing and asthma in early childhood, according to new research. “Our studies on t...
Wildfire PM2.5 Linked to Increase in Incidence of Asthma ED Visits
MONDAY, Aug. 28, 2023 – Wildfire fine particulate matter (PM2.5) is associated with a significant increase in the incidence of same-day asthma emergency department (ED) visits, but the increase was...
Exercise Benefits Patients With Asthma According To Review
MONDAY, Aug. 14, 2023 – Yoga and breathing control practices, in combination with aerobic training, may benefit people with asthma seeking to improve their lung function, according to a review...
FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of Asthma
London UK 9 September 2020 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy...
FDA Approves ProAir Digihaler (albuterol sulfate) as the First and Only Digital Inhaler with Built-In Sensors
JERUSALEM--(BUSINESS WIRE)--Dec 21, 2018--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (a...
FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ – Sanofi (EURONEXT: SAN) (NYSE: SNY) The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy ...
GSK Receives FDA Approval of Arnuity Ellipta for Asthma in Children From 5 Years of Age
London, UK 21 May 2018 --GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled...
FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma
November 14, 2017 – AstraZeneca (NYSE:AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra...
FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
RIDGEFIELD, Conn., February 16, 2017 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat for the long-term,...
Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ArmonAir...
Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo...
Symbicort Approved for the Treatment of Asthma in Patients 6 to 12 Years of Age
26 January 2017 – AstraZeneca today announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of pediatric exclusivity for Symbicort (budesonide/formoterol)...
FDA Approves Cinqair (reslizumab) to Treat Severe Asthma
March 23, 2016 – The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
methylprednisolone, albuterol, Singulair, Symbicort, Medrol, Dupixent, Xolair, Advair Diskus, fluticasone, Advair HFA, montelukast, Ventolin, budesonide, omalizumab